The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...

Genetic changes are a significant cause of infertility, impacting over 15% of the global population. TLE6, a major protein ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

In gene and cell therapy, RNP-mediated CRISPR gene editing is quickly emerging as the new norm. For many gene editing firms, GenScript has created hundreds of Cas9, Cas12a, Cas13a, MAD7 ...

Researchers at the Experimental and Clinical Research Center (ECRC), a joint institution of the Max Delbrück Center and ...

Intellia Therapeutics, Inc. NTLA lost 21.6% in a week as investors were disappointed with the company’s plans for portfolio ...

May 30, 2024 — Researchers have developed a novel version of a key CRISPR gene-editing protein that shows efficient editing activity and is small enough to be packaged within a non-pathogenic ...

Researchers at the Experimental and Clinical Research Center in Berlin are developing a targeted treatment for muscular ...

CRISPR gene-editing technology presents a possible solution for feeding a growing population, but incorporating CRISPR into ...

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock. This data can help you ...

In October, Intellia reported phase 2 results with NTLA-2002 – which is pitching to become the first approved in vivo CRISPR ...

Bank of America Securities analyst Alec Stranahan maintained a Sell rating on Editas Medicine (EDIT – Research Report) yesterday and set a ...